Mortality and the risk of malignancy in autoimmune liver diseases: A population-based study in Canterbury, New Zealand

Hepatology

Volumn 55, Issue 2, 2012, Pages 522-529

  Ngu, Jing Hieng ^a,b   Gearry, Richard Blair ^a,b   Frampton, Chris Miles ^b   Malcolm Stedman, Catherine Ann ^a,b  

^a CHRISTCHURCH HOSPITAL   (New Zealand)

^b UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

URSODEOXYCHOLIC ACID;

ADOLESCENT; ADULT; AGED; ARTICLE; AUTOIMMUNE HEPATITIS; B CELL LYMPHOMA; BILE DUCT CARCINOMA; CANCER RISK; CHRONIC LYMPHATIC LEUKEMIA; COHORT ANALYSIS; COLORECTAL CARCINOMA; FEMALE; FOLLOW UP; GALLBLADDER CARCINOMA; HUMAN; LIVER CELL CARCINOMA; MALE; MORTALITY; MYELOID LEUKEMIA; NEW ZEALAND; PRIMARY BILIARY CIRRHOSIS; PRIMARY SCLEROSING CHOLANGITIS; PRIORITY JOURNAL; SKIN CANCER; STANDARDIZED INCIDENCE RATIO; STANDARDIZED MORTALITY RATIO;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHOLANGITIS, SCLEROSING; COHORT STUDIES; FEMALE; HEPATITIS, AUTOIMMUNE; HUMANS; LIVER CIRRHOSIS, BILIARY; MALE; MIDDLE AGED; NEOPLASMS; NEW ZEALAND; RISK ASSESSMENT; YOUNG ADULT;

EID: 84856393639     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.24743     Document Type: Article

References (40)

1. Roberts SK, Therneau TM, Czaja AJ. Prognosis of histological cirrhosis in type 1 autoimmune hepatitis. Gastroenterology 1996; 110: 848-857.
2. Kanzler S, Lohr H, Gerken G, Galle PR, Lohse AW. Long-term management and prognosis of autoimmune hepatitis (AIH): a single center experience. Z Gastroenterol 2001; 39: 339-341, 344-338.
3. Floreani A, Niro G, Rosa Rizzotto E, Antoniazzi S, Ferrara F, Carderi I, et al. Type I autoimmune hepatitis: clinical course and outcome in an Italian multicentre study. Aliment Pharmacol Ther 2006; 24: 1051-1057.
4. Hoeroldt B, McFarlane E, Dube A, Basumani P, Karajeh M, Campbell MJ, et al. Long-term outcomes of patients with autoimmune hepatitis managed at a nontransplant center. Gastroenterology 2011; 140: 1980-1989.
5. Mills PR, Boyle P, Quigley EM, Birnie GG, Jarrett F, Watkinson G, et al. Primary biliary cirrhosis: an increased incidence of extrahepatic malignancies? J Clin Pathol 1982; 35: 541-543.
6. Goudie BM, Burt AD, Boyle P, Macfarlane G, Birnie GG, Mills PR, et al. Breast cancer in women with primary biliary cirrhosis. Br Med J 1985; 291: 1597-1598.
7. Wolke AM, Schaffner F, Kapelman B, Sacks HS. Malignancy in primary biliary cirrhosis. High incidence of breast cancer in affected women. Am J Med 1984; 76: 1075-1078.
8. Floreani A, Baragiotta A, Baldo V, Menegon T, Farinati F, Naccarato R. Hepatic and extrahepatic malignancies in primary biliary cirrhosis. HEPATOLOGY 1999; 29: 1425-1428.
9. Howel D, Metcalf JV, Gray J, Newman WL, Jones DE, James OF. Cancer risk in primary biliary cirrhosis: a study in northern England. Gut 1999; 45: 756-760.
10. Jackson H, Solaymani-Dodaran M, Card TR, Aithal GP, Logan R, West J. Influence of ursodeoxycholic acid on the mortality and malignancy associated with primary biliary cirrhosis: a population-based cohort study. HEPATOLOGY 2007; 46: 1131-1137.
11. Floreani A, Caroli D, Variola A, Rizzotto ER, Antoniazzi S, Chiaramonte M, et al. A 35-year follow-up of a large cohort of patients with primary biliary cirrhosis seen at a single centre. Liver Int 2011; 31: 361-368.
12. Prince M, Chetwynd A, Newman W, Metcalf JV, James OF. Survival and symptom progression in a geographically based cohort of patients with primary biliary cirrhosis: follow-up for up to 28 years. Gastroenterology 2002; 123: 1044-1051.
13. Prince MI, Chetwynd A, Craig WL, Metcalf JV, James OF. Asymptomatic primary biliary cirrhosis: clinical features, prognosis, and symptom progression in a large population based cohort. Gut 2004; 53: 865-870.
14. Werner M, Almer S, Prytz H, Lindgren S, Wallerstedt S, Bjornsson E, et al. Hepatic and extrahepatic malignancies in autoimmune hepatitis. A long-term follow-up in 473 Swedish patients. J Hepatol 2009; 50: 388-393.
15. Ngu JH, Bechly K, Chapman BA, Burt MJ, Barclay ML, Gearry RB, et al. Population-based epidemiology study of autoimmune hepatitis: a disease of older women? J Gastroenterol Hepatol 2010; 25: 1681-1686.
16. Ngu JH, Gearry RB, Wright AJ, Stedman CAM. Inflammatory bowel disease is associated with poor outcomes of patients with primary sclerosing cholangitis. Clin Gastroenterol Hepatol 2011;9:1092-1097.
17. Ngu JH, Wright A, Gearry RB, Chapman BA, Burt MJ, Barclay ML, et al. Primary biliary cirrhosis in Canterbury, New Zealand: a population-based study. J Gastroenterol Hepatol 2010; 25: A177.
18. Ministry of Health. Health Expenditure Trends in New Zealand 1996-2006. In: Ministry of Health, ed. Wellington, New Zealand; 2008.
19. Gearry RB, Richardson A, Frampton CM, Collett JA, Burt MJ, Chapman BA, et al. High incidence of Crohn's disease in Canterbury, New Zealand: results of an epidemiologic study. Inflamm Bowel Dis 2006; 12: 936-943.
20. Alvarez F, Berg PA, Bianchi FB, Bianchi L, Burroughs AK, Cancado EL, et al. International Autoimmune Hepatitis Group report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol 1999; 31: 929-938.
21. Metcalf J, James O. The geoepidemiology of primary biliary cirrhosis. Sem Liver Dis 1997; 17: 13-22.
22. Bambha K, Kim WR, Talwalkar J, Torgerson H, Benson JT, Therneau TM, et al. Incidence, clinical spectrum, and outcomes of primary sclerosing cholangitis in a United States community. Gastroenterology 2003; 125: 1364-1369.
23. Hartz AJ, Giefer EE, Hoffmann RG. A comparison of two methods for calculating expected mortality. Stat Med 1983; 2: 381-386.
24. Montano-Loza AJ, Carpenter HA, Czaja AJ. Improving the end point of corticosteroid therapy in type 1 autoimmune hepatitis to reduce the frequency of relapse. Am J Gastroenterol 2007; 102: 1005-1012.
25. Manns MP, Woynarowski M, Kreisel W, Lurie Y, Rust C, Zuckerman E, et al. Budesonide induces remission more effectively than prednisone in a controlled trial of patients with autoimmune hepatitis. Gastroenterology 2010; 139: 1198-1206.
26. Card TR, Solaymani-Dodaran M, West J. Incidence and mortality of primary sclerosing cholangitis in the UK: a population-based cohort study. J Hepatol 2008; 48: 939-944.
27. Myers RP, Shaheen AA, Fong A, Burak KW, Wan A, Swain MG, et al. Epidemiology and natural history of primary biliary cirrhosis in a Canadian health region: a population-based study. HEPATOLOGY 2009; 50: 1884-1892.
28. Floreani A, Caroli D, Variola A, Rizzotto ER, Antoniazzi S, Chiaramonte M, et al. A 35-year follow-up of a large cohort of patients with primary biliary cirrhosis seen at a single centre. Liver Int 2011; 3: 361-368.
29. Bergquist A, Ekbom A, Olsson R, Kornfeldt D, Loof L, Danielsson A, et al. Hepatic and extrahepatic malignancies in primary sclerosing cholangitis. J Hepatol 2002; 36: 321-327.
30. Loof L, Adami HO, Sparen P, Danielsson A, Eriksson LS, Hultcrantz R, et al. Cancer risk in primary biliary cirrhosis: a population-based study from Sweden. HEPATOLOGY 1994; 20: 101-104.
31. Nijhawan PK, Therneau TM, Dickson ER, Boynton J, Lindor KD. Incidence of cancer in primary biliary cirrhosis: the Mayo experience. HEPATOLOGY 1999; 29: 1396-1398.
32. Van Dam GM, Gips CH. Primary biliary cirrhosis in the Netherlands. An analysis of associated diseases, cardiovascular risk, and malignancies on the basis of mortality figures. Scand J Gastroenterol 1997; 32: 77-83.
33. Piscaglia F, Sagrini E. Malignancies in primary biliary cirrhosis. Eur J Gastroenterol Hepatol 2008; 20: 1-4.
34. Shibuya A, Tanaka K, Miyakawa H, Shibata M, Takatori M, Sekiyama K, et al. Hepatocellular carcinoma and survival in patients with primary biliary cirrhosis. HEPATOLOGY 2002; 35: 1172-1178.
35. Cavazza A, Caballeria L, Floreani A, Farinati F, Bruguera M, Caroli D, et al. Incidence, risk factors, and survival of hepatocellular carcinoma in primary biliary cirrhosis: comparative analysis from two centers. HEPATOLOGY 2009; 50: 1162-1168.
36. Turissini SB, Kaplan MM. Hepatocellular carcinoma in primary biliary cirrhosis. Am J Gastroenterol 1997; 92: 676-678.
37. Wang KK, Czaja AJ, Beaver SJ, Go VL. Extrahepatic malignancy following long-term immunosuppressive therapy of severe hepatitis B surface antigen-negative chronic active hepatitis. HEPATOLOGY 1989; 10: 39-43.
38. Smedby KE, Askling J, Mariette X, Baecklund E. Autoimmune and inflammatory disorders and risk of malignant lymphomas-an update. J Intern Med 2008; 264: 514-527.
39. Martin DN, Mikhail IS, Landgren O. Autoimmunity and hematologic malignancies: associations and mechanisms. Leuk Lymphoma 2009; 50: 541-550.
40. Czaja AJ, Manns MP. Advances in the diagnosis, pathogenesis, and management of autoimmune hepatitis. Gastroenterology 2010; 139: 58-72 e54.